Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sonnet Biotherapeutics Holdings Inc
(NQ:
SONN
)
0.7695
+0.0194 (+2.59%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sonnet Biotherapeutics Holdings Inc
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Why Greenland Technologies Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket
August 16, 2024
Via
Benzinga
SONN Stock Earnings: Sonnet BioTherapeutics Beats EPS for Q3 2024
August 14, 2024
SONN stock results show that Sonnet BioTherapeutics beat analyst estimates for earnings per share the third quarter of 2024.
Via
InvestorPlace
Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
August 14, 2024
From
Sonnet BioTherapeutics Holdings, Inc.
Via
GlobeNewswire
Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study
July 24, 2024
From
Sonnet BioTherapeutics Holdings, Inc.
Via
GlobeNewswire
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview
October 31, 2023
Via
ACCESSWIRE
12 Health Care Stocks Moving In Friday's Pre-Market Session
June 21, 2024
Via
Benzinga
Dow Jumps Over 300 Points; Zapp Electric Vehicles Group Shares Spike Higher
June 20, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
June 20, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
June 20, 2024
Via
Benzinga
Gold Rises 1%; Accenture Shares Surge After Q3 Results
June 20, 2024
Via
Benzinga
Dow Edges Lower; US Current Account Deficit Widens In Q1
June 20, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds
June 20, 2024
From
Sonnet BioTherapeutics Holdings, Inc.
Via
GlobeNewswire
Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain
June 13, 2024
From
Sonnet BioTherapeutics Holdings, Inc.
Via
GlobeNewswire
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
May 28, 2024
From
Sonnet BioTherapeutics Holdings, Inc.
Via
GlobeNewswire
Sonnet BioTherapeutics Announces Review of Strategic Alternatives
May 22, 2024
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target
May 20, 2024
Via
ACCESSWIRE
SONN Stock Earnings: Sonnet BioTherapeutics Misses EPS for Q2 2024
May 15, 2024
SONN stock results show that Sonnet BioTherapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update
May 14, 2024
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference
May 06, 2024
Via
ACCESSWIRE
Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting
March 19, 2024
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective
March 11, 2024
Via
ACCESSWIRE
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers
February 29, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
February 14, 2024
Via
Benzinga
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
February 14, 2024
Via
ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 13, 2024
Via
Benzinga
Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
December 21, 2023
Via
ACCESSWIRE
Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update
December 14, 2023
Via
ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's After-Market Session
November 28, 2023
Via
Benzinga
What's Happening With Sonnet BioTherapeutics (SONN) Shares?
October 26, 2023
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares are trading lower by 8.5% to $1.18 Thursday morning on downward momentum.
Via
Benzinga
Dow Falls Over 100 Points; Alphabet Shares Tumble After Q3 Results
October 25, 2023
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Wednesday. The Dow traded down 0.35% to 33,025.71 while the NASDAQ fell 2.45% to 12,817.76....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.